United Therapeutics

YTD

ALL

Trade United Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About UTHR

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin.

CEO

Martine A. Rothblatt

CEOMartine A. Rothblatt

Employees

1,400

Employees1,400

Headquarters

Silver Spring, Maryland

HeadquartersSilver Spring, Maryland

Founded

1996

Founded1996

Employees

1,400

Employees1,400

UTHR Key Statistics

Market cap

24.14B

Market cap24.14B

Price-Earnings ratio

21.25

Price-Earnings ratio21.25

Dividend yield

—

Dividend yield—

Average volume

482.63K

Average volume482.63K

High today

$576.49

High today$576.49

Low today

$565.26

Low today$565.26

Open price

$576.49

Open price$576.49

Volume

334.14K

Volume334.14K

52 Week high

$609.35

52 Week high$609.35

52 Week low

$272.12

52 Week low$272.12

Stock Snapshot

United Therapeutics(UTHR) stock is priced at $568.58, giving the company a market capitalization of 24.14B. It carries a P/E multiple of 21.25.

On 2026-05-15, United Therapeutics(UTHR) stock traded between a low of $565.26 and a high of $576.49. Shares are currently priced at $568.58, which is +0.6% above the low and -1.4% below the high.

The United Therapeutics(UTHR)'s current trading volume is 334.14K, compared to an average daily volume of 482.63K.

In the last year, United Therapeutics(UTHR) shares hit a 52-week high of $609.35 and a 52-week low of $272.12.

UTHR News

Investing.com 1d

Martine Rothblatt, CEO, sells $5.5m in United Therapeutics stock - Investing.com

...

TipRanks 2d

Insider Shake-Up at United Therapeutics Sparks Investor Buzz

New insider activity at United Therapeutics ( (UTHR) ) has taken place on May 13, 2026. Unlock hedge fund-level data and powerful investing tools for smarter,...

Simply Wall St 4d

United Therapeutics Phase 3 Lung Data Could Reshape Pulmonary Franchise Outlook

United Therapeutics (NasdaqGS:UTHR) plans to present new phase 3 clinical data for Tyvaso (inhaled treprostinil for idiopathic pulmonary fibrosis) and ralinepag...

Analyst ratings

81%

of 16 ratings

Buy

81.3%

Hold

18.8%

Sell

People also own

Based on the portfolios of people who own UTHR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.